TET2 and prostate cancer: In order to study DNA methylations as markers of prostate carcinogenesis, CRISPR/Cas9 knock-out of tumor-suppressor TET2, which is involved in DNA demethylation and is usually poorly expressed in prostate cancer cells, has been carried out and helped to identify highly altered genes in prostate cancer.